NCT01107457.
Trial name or title | A Dose‐Ranging And Efficacy Study of LY2439821 (An Anti‐IL‐17 Antibody) In Patients With Moderate‐To‐Severe Psoriasis |
Methods | This is a randomised, placebo‐controlled, double‐blind trial. Participants will be evaluated for treatment efficacy at multiple visits, and the primary end point will be evaluated at week 16. Participants will be followed an additional 16 to 24 weeks (32 to 40 weeks in total) after the completion of dosing in order to continue safety monitoring and to determine the duration of treatment efficacy. |
Participants |
Inclusion criteria of the trial
|
Interventions |
|
Outcomes |
Outcomes of the trial
|
Starting date | April 2010 |
Contact information | Eli Lilly & Co. Study Director: phone CTLILLY (+1 877 285 4559) or phone +1 317 615 4559 |
Notes | Status: This trial is not yet recruiting. |